βIGH3, a TGF-β inducible gene, is overexpressed in lung cancer

Japanese Journal of Clinical Oncology

Volumn 32, Issue 3, 2002, Pages 85-89

  Sasaki, Hidefumi ^a   Kobayashi, Yoshihiro ^a   Nakashima, Yoshiaki ^a   Moriyama, Satoru ^a   Yukiue, Haruhiro ^a   Kaji, Masahiro ^a   Kiriyama, Masanobu ^a   Fukai, Ichiro ^a   Yamakawa, Yosuke ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

IGH3; Invasion; LightCycler; Lung cancer; TGF

Indexed keywords

PROTEIN BETA IGH3; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; BETAIG H3 PROTEIN; BETAIG-H3 PROTEIN; MESSENGER RNA; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; REAL TIME POLYMERASE CHAIN REACTION; CANCER INVASION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 0036517815     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyf021     Document Type: Article

References (22)

1. Ginsberg RJ, Kris MK, Armstrong JG. Cancer of the lung. In: De Vita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia, PA: Lippincott 1993:673-82.
2. Yasuda K, Ayabe H, Ide H, Uchida Y, on behalf of the Japanese Association for Thoracic Surgery. Thoracic and cardiovascular surgery in Japan during 1998. Annual Report by the Japanese Association for Thoracic Surgery. Jpn J Thorac Cardiovasc Surg 1998;48:401-15.
3. Postus PE, on behalf of the Lung Cancer Cooperative Group of the EORTC. The experience of the Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Chest Suppl 1997;113:28S-31S.
4. Reiss M. TGF-β and cancer. Microbes Infect 1999;1:1327-47.
5. Reiss M. Transforming growth factor-beta and cancer: a love-hate relationship? Oncol Res 1997;9:447-57.
6. Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD, Purchio AF. cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol 1992;11:511-22.
7. LeBaron RG, Benzverkov KI, Zimber MP, Pavelec R, Skonier J, Purchio AF. Beta IG-H3, a novel secretory protein inducible by transforming growth factor-beta, is present in normal skin and promotes the adhesion and spreading of dermal fibroblasts in vitro. J Invest Dermatol 1995;104:844-9.
8. Kitahara O, Furukawa Y, Tanaka T, Kihara C, Ono K, Yanagawa R, et al. Alternations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissue and normal epithelia. Cancer Res 2001;61:3544-9.
9. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu H-L, Muniskin A, et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001;61:5168-78.
10. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997;22:176-81.
11. General Rules for Clinical and Pathological Recording of Lung Cancer, 5th ed, vol 5. Tokyo: Japan Lung Cancer Society 1999;5:1-177.
12. Pierce DF Jr, Gorska AE, Chytil A, Meise KS, Page DL, Coffey RJ Jr, et al. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci USA 1995;92:4254-8.
13. Kulkarni AB, Huh CG, Berker D, Geiser A, Lyght M, Flanders KC, et al. Transforming growth factor beta 1 null mutations in mice cause excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993;90:770-4.
14. Glick AB, Lee MM, Darwiche N, Kulkarni AB, Karlsson S, Yuspa SH. Targeted deletion of the TGF-beta-1 gene causes rapid progression to squamous cell carcinoma. Gene Dev 1994;8:2429-40.
15. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karllsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995;121:1845-54.
16. Tang B, Bottinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR, et al. Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency. Nature Med 1998;4:802-7.
17. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 1996;7:93-102.
18. Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 1996;16:47-59.
19. Takanami I, Tanaka F, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T, et al. Transforming growth factor-beta isoform expressions in pulmonary adenocarcinomas as prognostic markers: an immunohistological study of one hundred and twenty patients. Oncology 1997;54:122-8.
20. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-betal level correlates with angiogenesis, tumor progression and prognosis in patients with non-small cell lung carcinoma. Cancer 2001;91:964-71.
21. Zinn K, McAllister L, Goodman CS. Sequence analysis and neural expression of fasciclin I in grasshopper and Drosophila. Cell 1988;53:577-83.
22. Sasaki H, Lo K-M, Chen LB, Auclair D, Nakashima Y, Moriyama S, et al. Expression of periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers. Jpn J Cancer Res 2001;92:869-73.